ESR1 and breast cancer: In 2013, a meta-analysis of women with high-risk breast cancer who underwent preventive therapy using selective estrogen receptor modulators showed that at the 65-month follow-up, the incidence of breast cancer had decreased to 38% (hazard ratio, 0.62; 95% confidence interval, 0.56–0.69) (29).